Compare SPRO & MHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPRO | MHF |
|---|---|---|
| Founded | 2013 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.5M | 153.7M |
| IPO Year | 2017 | N/A |
| Metric | SPRO | MHF |
|---|---|---|
| Price | $2.70 | $6.96 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 408.3K | 47.6K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.29% |
| EPS Growth | ★ 111.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $66,802,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $300.00 | N/A |
| P/E Ratio | $16.23 | ★ N/A |
| Revenue Growth | ★ 39.24 | N/A |
| 52 Week Low | $0.65 | $6.61 |
| 52 Week High | $3.09 | $7.64 |
| Indicator | SPRO | MHF |
|---|---|---|
| Relative Strength Index (RSI) | 56.63 | 55.42 |
| Support Level | $2.15 | $6.96 |
| Resistance Level | $2.70 | $7.05 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 85.53 | 67.86 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.